By early 2026, the domestic generic injectable sector has emerged as a major player on the global stage, with exports reaching an all-time high to markets in Southeast Asia, Africa, and Latin America. This 2026 surge is driven by a series of bilateral "Mutual Recognition Agreements" (MRAs) that allow for the fast-track approval of locally manufactured parenteral drugs in several emerging...
Portuguese (Brazil) 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek